Age: 72.0
Sex: M
Vaccine: MENB, MENB, MNQ, MNQ
Symptoms: Circumstance or information capable of leading to medication error, Product administered to patient of inappropriate age
Clinical narrative: plan is to administer next dose about 2-4 weeks after they finish chemotherapy in June (2nd dose bexsero and Menveo); plan is to administer next dose about 2-4 weeks after they finish chemotherapy in June (2nd dose bexsero and Menveo); 72 year old male patient received 1st dose Bexsero/ Menveo; This non-serious case was reported by a physician via call center representative and described the occurrence of inappropriate age at vaccine administration in a 72-year-old male patient who received Men B NVS (Bexsero) (batch number TH9NR, expiry date 31-JAN-2027) for prophylaxis.   Co-suspect products included Men ACWY-CRM NVS (Menveo) (batch number 3553D, expiry date 28-FEB-2025) for prophylaxis, Men B NVS (Bexsero) for prophylaxis and Men ACWY-CRM NVS (Menveo) for prophylaxis.   The patient's past medical history included pancreatectomy (In January 2024 the patient underwent pancreatectomy), splenectomy (In January 2024 the patient underwent Splenectomy) and chemotherapy. Concurrent medical conditions included pancreatic cancer (patient was diagnosed about 9 months ago with pancreatic cancer).   On 18-JAN-2024, the patient received the 1st dose of Bexsero and the 1st dose of Menveo. On an unknown date, the patient did not receive the 2nd dose of Bexsero and the 2nd dose of Menveo. On 18-JAN-2024, an unknown time after receiving Bexsero and Menveo and not applicable after receiving Bexsero and Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: 72 year old male patient received 1st dose Bexsero/ Menveo). On an unknown date, the patient experienced circumstance or information capable of leading to medication error (Verbatim: plan is to administer next dose about 2-4 weeks after they finish chemotherapy in June (2nd dose bexsero and Menveo)) and inappropriate age at vaccine administration (Verbatim: plan is to administer next dose about 2-4 weeks after they finish chemotherapy in June (2nd dose bexsero and Menveo)). The outcome of the inappropriate age at vaccine administration, circumstance or information capable of leading to medication error and inappropriate age at vaccine administration were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 16-MAY-2024 The physician reported that the 72 years old patient underwent pancreatectomy and splenectomy and prior to leaving hospital received Bexsero and Menveo vaccine, which led to inappropriate age at vaccine administration. The recommendation given to the patient to get a second dose of each vaccine approximately one month after discharge from the hospital. Approximately 4-6 weeks after hospital discharge, the patient resumed chemotherapy. The oncologist advised patient not to get second doses yet, with concerns regarding possible diminished immune response, the plan was to administer next dose about 2-4 weeks after they finish chemotherapy in June, which led to circumstance or information capable of leading to medication error and inappropriate age at vaccine administration. The reporter consented to follow up.